Presidential Advisory Council on HIV/AIDS, International Issues Subcommittee [Transcript]

26
1 experience developing vaccines. He needs to bring together
2 the expertise of vaccine developers, many of whom aren't
3 involved with the kind of work like Dr. Belshe is involved
4 with. Those people ought to be given the capacity, in
5 collaboration with the ethicists, the public health people,
6 the basic scientists, to work together to develop the field
7 trials.
8 That's the target, but we'll never get there if
9 we don't have the field trials, and people with vaccine
10 development experience are fully capable of drawing on the
11 expertise of CDC for epidemiology, the expertise from NIH
12 for the various laboratory issues, from FDA because
13 ultimately whatever you want to develop you want to have
14 licensed, and perhaps also USAID, perhaps also the
15 Department of Defense.
16 There are tremendous resources, but they need
17 coordination, and most of all, they need leadership,
18 leadership that says that we need a vaccine, let's move for
19 that vaccine, instead of constantly finding reasons for not
20 pursuing it.
21 MR. FOGEL: Helen, you had a question?
22 MS. MIRAMONTES; No, it was about -- I wanted
23 to talk to you privately about the 076 trials later.
24 MR. FOGEL: Does anybody else have a question?
25 Ron?
26 PARTICIPANT: Just quickly, could you mention

FREILICHER & ASSOCIATES. COURT REPORTERS
[phone]